# Andrew Reaume

> Andrew Reaume is the co-founder, President and CEO of Melior Discovery, an Exton, Pennsylvania preclinical contract research organization built around theraTRACE, a multiplexed in vivo phenotypic screening platform that runs a single drug candidate through a battery of animal disease models at once to uncover unexpected therapeutic uses. A geneticist by training with a Wharton MBA, he conceived the idea at Pfizer, left in 2005 to build it, and has since raised over $15 million in capital, closed more than $40 million in partnering deals, and pushed a repurposed compound, MLR-1023, into Phase 2 diabetes trials.

- **Role:** President & CEO, Co-Founder at Melior Discovery
- **Organizations:** Melior Discovery, Inc., Melior Pharmaceuticals I, Inc., Melior Pharmaceuticals II, LLC, Pfizer, Inc. (former), Cephalon (former)
- **Nationality:** American
- **Education:** PhD in Genetics, University of Connecticut, MBA, Entrepreneurial Management (with honors), The Wharton School, University of Pennsylvania
- **Known for:** Co-founded Melior Discovery (2005) and grew it from a discovery-stage R&D operation to a clinical-stage enterprise, Raised over $15 million in investment capital, Completed over $40 million in partnering deals, including research partnerships with global pharmaceutical companies

## Career timeline

- **1993** — Joined Cephalon, working in R&D creating animal models of neurodegenerative disease and identifying in-licensing opportunities
- **1999** — Moved to Pfizer as Senior Business Analyst in genomics and proteomic sciences; conceived a platform to characterize genetically modified mice as disease models
- **2003** — Earned MBA from the Wharton School in Entrepreneurial Management
- **2005** — Left Pfizer and co-founded Melior Discovery with Michael Saporito to build the theraTRACE phenotypic screening platform
- **2009** — FDA cleared the IND for MLR-1023, a repurposed kinase activator for type 2 diabetes
- **2013** — Licensed MLR-1023 to Bukwang Pharmaceutical
- **2016** — Reported positive Phase 2a results for MLR-1023 in diabetic subjects

## Achievements

- Co-founded Melior Discovery (2005) and grew it from a discovery-stage R&D operation to a clinical-stage enterprise
- Raised over $15 million in investment capital
- Completed over $40 million in partnering deals, including research partnerships with global pharmaceutical companies
- Built the theraTRACE multiplexed in vivo phenotypic screening platform
- Advanced repurposed compound MLR-1023 through two Phase 2 studies involving 600+ subjects across 80 clinical sites in two countries
- Serves as President & CEO of two spinout companies, Melior Pharmaceuticals I and II

## Latest updates

- **2023** — Melior Discovery recognized among top preeminent CROs

## Links

- Website: https://meliordiscovery.com
- LinkedIn: http://www.linkedin.com/in/andrew-reaume-38b1a72

---

Profile page: https://yespress.io/andrew-reaume
Published by YesPress — https://yespress.io
Last updated: 2026-06-25